Fuji Pharma Co., Ltd. (TYO:4554)
Japan · Delayed Price · Currency is JPY 1,857.00
-21.00 (-1.12%)
Nov 13, 2026, 3:30 PM JST
Fuji Pharma Income Statement
Financials in millions JPY. Fiscal year is October - September.
Millions JPY. Fiscal year is Oct - Sep.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
| 62,386 | 51,677 | 46,138 | 40,889 | 35,426 | |
Revenue Growth | 20.72% | 12.01% | 12.84% | 15.42% | 4.23% |
Cost of Revenue | 38,065 | 30,914 | 28,294 | 24,374 | 20,867 |
Gross Profit | 24,321 | 20,763 | 17,844 | 16,515 | 14,559 |
Selling, General & Admin | 12,359 | 10,957 | 9,231 | 8,331 | 7,355 |
Research & Development | 4,059 | 3,344 | 3,401 | 3,184 | 2,485 |
Amortization of Goodwill & Intangibles | - | 90 | 337 | 316 | 283 |
Operating Expenses | 17,966 | 15,773 | 13,963 | 12,656 | 10,781 |
Operating Income | 6,355 | 4,990 | 3,881 | 3,859 | 3,778 |
Interest Expense | -400 | -330 | -196 | -121 | -77 |
Interest & Investment Income | - | - | - | 77 | 43 |
Currency Exchange Gain (Loss) | 43 | 35 | 74 | 127 | 227 |
Other Non Operating Income (Expenses) | 304 | 85 | 53 | 212 | 39 |
EBT Excluding Unusual Items | 6,302 | 4,780 | 3,812 | 4,154 | 4,010 |
Gain (Loss) on Sale of Investments | -2,000 | - | 3,118 | - | - |
Asset Writedown | -1,146 | -776 | 572 | 364 | -288 |
Legal Settlements | - | - | - | -120 | - |
Other Unusual Items | -1 | -4 | 772 | - | - |
Pretax Income | 3,155 | 4,000 | 8,274 | 4,398 | 3,722 |
Income Tax Expense | 324 | 1,000 | 2,128 | 963 | 1,026 |
Net Income | 2,831 | 3,000 | 6,146 | 3,435 | 2,696 |
Net Income to Common | 2,831 | 3,000 | 6,146 | 3,435 | 2,696 |
Net Income Growth | -5.63% | -51.19% | 78.92% | 27.41% | 10.85% |
Shares Outstanding (Basic) | 25 | 24 | 24 | 24 | 24 |
Shares Outstanding (Diluted) | 25 | 24 | 24 | 24 | 24 |
Shares Change | 4.35% | 0.38% | 0.04% | 0.03% | -9.58% |
EPS (Basic) | 111.18 | 122.93 | 252.81 | 141.35 | 110.98 |
EPS (Diluted) | 111.18 | 122.93 | 252.81 | 141.35 | 110.98 |
EPS Growth | -9.56% | -51.37% | 78.86% | 27.37% | 22.60% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Free Cash Flow | 4,082 | 3,820 | 1,373 | -1,410 | -5,755 |
Free Cash Flow Per Share | 160.31 | 156.54 | 56.48 | -58.02 | -236.90 |
Dividend Per Share | - | 45.500 | 42.500 | 37.000 | 35.000 |
Dividend Growth | - | 7.06% | 14.87% | 5.71% | 20.69% |
Gross Margin | 38.98% | 40.18% | 38.67% | 40.39% | 41.10% |
Operating Margin | 10.19% | 9.66% | 8.41% | 9.44% | 10.66% |
Profit Margin | 4.54% | 5.80% | 13.32% | 8.40% | 7.61% |
Free Cash Flow Margin | 6.54% | 7.39% | 2.98% | -3.45% | -16.25% |
EBITDA | 10,562 | 8,955 | 7,561 | 6,882 | 6,523 |
EBITDA Margin | 16.93% | 17.33% | 16.39% | 16.83% | 18.41% |
D&A For EBITDA | 4,207 | 3,965 | 3,680 | 3,023 | 2,745 |
EBIT | 6,355 | 4,990 | 3,881 | 3,859 | 3,778 |
EBIT Margin | 10.19% | 9.66% | 8.41% | 9.44% | 10.66% |
Effective Tax Rate | 10.27% | 25.00% | 25.72% | 21.90% | 27.57% |